NICE TA606 lanadelumab cut UK HAE attack frequency from 12 a year to 1.5, an 87% reduction.
Hereditary angioedema is a genetic disorder of the complement and kinin cascade causing recurrent, unpredictable subcutaneous and submucosal swelling episodes, with laryngeal attacks carrying fatal risk if untreated. The UK HAE Alliance estimates 1,500 to 2,000 UK patients, approximately 1 in 32,000 of the population. HAE with C1-inhibitor deficiency, Type 1 or 2, accounts for roughly 85% of cases, with HAE with normal C1-INH, either oestrogen-related or FXII mutation-driven, making up the remaining 15%.
NHS Genomic Medicine Service offers free SERPING1 gene testing as part of the immunodeficiency and angioedema gene panel, driving one of the highest diagnosis rates globally. UK HAE Alliance survey data show mean attack frequency falling from 12 attacks a year before lanadelumab to 1.5 attacks a year after NICE TA606 commissioning, an 87% reduction consistent with the HELP trial, with annual emergency room attendance for laryngeal HAE falling from 45% to under 5%.
One NICE decision cut UK HAE attacks by 87%.
Five questions this report answers:
Q1 - What is the size of the NHS-commissioned HAE prophylaxis population pending berotralstat review?
Q2 - How does NHS GMS SERPING1 cascade testing drive UK HAE diagnosis rates?
Q3 - What has NICE TA606 lanadelumab commissioning changed about UK HAE disease burden?
Q4 - How has NICE TA606 lanadelumab changed UK HAE disease burden under NHS care?
Q5 - How far has laryngeal HAE ER attendance fallen since NICE TA606 commissioning?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#HAE #HereditaryAngioedema #NICE #NHS #UKHealthcare #DiseaseLandscape
Live report page: https://axlrx.ai/hereditary-angioedema/uk/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
KFSH&RC's HAE registry finds 3.8 relatives per index case, double Europe's rate, yet fewer than 200 GCC patients are confirmed.
Hereditary angioedema is an autosomal dominant disorder of C1 esterase inhibitor deficiency or dysfunction, producing recurrent, unpredictable attacks of subcutaneous and submucosal swelling. Background prevalence is roughly 1 in 50,000, but GCC family structures, an average of three to four children per family plus extended-family clustering, mean a single index diagnosis carries direct implications for six to twelve relatives. The KFSH&RC HAE registry documents an average of 3.8 affected family members identified per index case, more than double the 1.8 average reported in Europe, making family cascade screening the highest-yield diagnostic strategy available in the region.
Untreated or under-treated GCC HAE patients experience six to twelve attacks per year, with laryngeal attacks, the life-threatening presentation carrying roughly 50% mortality if untreated, accounting for approximately 30% of episodes, a higher share than most global series. GCC emergency physicians rarely include HAE in the differential for laryngeal oedema, and general practitioners typically do not order the C4, C1-INH level, and C1-INH functional assay panel required for diagnosis unless a patient is referred to specialist allergy or immunology services. The result is an estimated 1,200 to 1,500 true GCC HAE patients, of whom fewer than 200 are confirmed.
Family screening, not new diagnostics, is the fastest way to find these patients.
Five questions this report answers:
Q1 - How many undiagnosed GCC HAE patients could family cascade screening identify after an index diagnosis?
Q2 - Why do GCC emergency and primary care physicians miss HAE in the differential for recurrent angioedema?
Q3 - What is the NPHC/MOH formulary trajectory for prophylactic therapy (lanadelumab) across GCC states?
Q4 - What diagnostic and access barriers define the addressable GCC HAE market?
Q5 - Why do laryngeal attacks account for roughly 30% of GCC HAE episodes, higher than global series?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#HAE #HereditaryAngioedema #RareDisease #GCCHealthcare #DiseaseLandscape
Live report page: https://axlrx.ai/hereditary-angioedema/gcc/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
Gaucher type 1 concentrates in the Ashkenazi Jewish founder population at 1 in 500-1,000, and the same genotype carries a near 20-fold Parkinson's risk.
Gaucher disease is an autosomal-recessive lysosomal storage disorder caused by biallelic mutations in GBA1, producing deficient acid beta-glucosidase and a buildup of glucosylceramide in macrophages that infiltrate spleen, liver and bone marrow. Disease divides into three types by neurological involvement: type 1, non-neuronopathic, accounts for more than 90% of patients, while types 2 and 3, far rarer, involve progressive central nervous system degeneration. Type 1 presents with splenomegaly, an enlarged liver, anaemia, low platelets and skeletal disease, not the CNS decline that defines the other two types.
Genotype predicts phenotype. The N370S variant, present on at least one allele, protects against neuronopathic disease and defines type 1; the L444P variant in the homozygous state is linked to the neuronopathic forms. Type 1 is markedly enriched in the Ashkenazi Jewish population, where carrier frequency runs about 1 in 12 to 15 and disease frequency roughly 1 in 500 to 1,000, versus 0.70 to 1.75 per 100,000 in the general population. Many 'asymptomatic' N370S homozygotes in fact have measurable anaemia or an enlarged spleen on evaluation. GBA1 is also the single most common genetic risk factor for Parkinson's disease, and diagnosed type 1 patients carry a lifetime risk ratio of 21.4.
The genotype that protects against neuronopathic Gaucher also predicts Parkinson's risk.
Five questions this report answers:
Q1 - How does the Ashkenazi Jewish founder effect concentrate US Gaucher prevalence?
Q2 - How does GBA1 genotype predict the type 1, 2 and 3 split?
Q3 - Where does the GBA1-Parkinson's link create screening opportunity?
Q4 - How common is Gaucher disease type 1 in the US?
Q5 - How do N370S and L444P variants differ in disease outcome?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#GaucherDisease #GBA1 #RareDisease #LysosomalStorageDisorder #AshkenaziJewish #USHealthcare
Live report page: https://axlrx.ai/gaucher-disease/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
Fabry disease has two faces: a classic childhood form, and a later-onset cardiac form that is far more common, yet mostly undiagnosed.
Fabry disease is an X-linked lysosomal storage disorder caused by GLA mutations that reduce or abolish alpha-galactosidase A activity, letting globotriaosylceramide build up in the vascular endothelium, kidney, heart and nervous system. Classic Fabry, with near-absent enzyme activity, presents in childhood with neuropathic pain, angiokeratoma and reduced sweating, progressing over decades to renal failure, hypertrophic cardiomyopathy and stroke. US prevalence of diagnosed classic Fabry is estimated at 5,000 to 10,000 patients, about 1 in 40,000 males, but that figure counts only the recognised population.
The larger, quieter story is the later-onset phenotype. Patients with residual enzyme activity often present in their fifties or sixties with isolated cardiac or kidney disease and are frequently missed. Long-term registry data show the leading cause of death shifting from renal failure toward cardiac disease as kidney management has improved. Because Fabry is X-linked, female heterozygotes are not merely carriers; many develop significant multi-organ disease, typically about a decade later than males. Layered on top is the treatment split: roughly 35% to 50% of patients carry a GLA mutation amenable to the oral chaperone migalastat, and the rest depend on intravenous enzyme replacement.
The undiagnosed later-onset cardiac pool may outsize the classic Fabry population.
Five questions this report answers:
Q1 - How large is the undiagnosed later-onset Fabry pool in the US?
Q2 - How does the Fabry organ timeline unfold from childhood pain to organ failure?
Q3 - How does GLA-mutation amenability split patients into oral-chaperone versus ERT-only groups?
Q4 - How common is diagnosed classic Fabry disease among US males?
Q5 - Why has cardiac disease overtaken renal failure as Fabry's leading cause of death?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#FabryDisease #LysosomalStorageDisorder #RareDisease #Nephrology #Cardiology #USHealthcare
Live report page: https://axlrx.ai/fabry-disease/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
The UK Fabry Outcome Survey tracks roughly 600 of the UK's estimated 800 diagnosed Fabry patients longitudinally.
Fabry disease is an X-linked lysosomal storage disorder caused by alpha-galactosidase A deficiency. An estimated 800 patients are diagnosed in the UK, managed through NHS Highly Specialised Services at lysosomal storage disorder centres in London, Manchester, Cambridge, Birmingham, Edinburgh, and Belfast. The UK Fabry Outcome Survey, a Sanofi-sponsored longitudinal registry, tracks roughly 600 UK patients, giving the UK one of the best-characterised Fabry populations globally, with data showing proteinuria in 55% of males and 35% of females at diagnosis, left ventricular hypertrophy in 60% of males, and neuropathic pain reported by 85% of patients at some point in their disease course.
The NHS Genomic Medicine Service offers free GLA gene testing for probands and first-degree relatives, with genetic counselling before and after testing. This drives a family-cascade yield the UK FOS estimates at 3-4 additional diagnosed relatives per index case, giving the UK the highest per-capita Fabry diagnosis rate in Europe. Both treatment pathways are NHS-commissioned: enzyme replacement therapy for all patients, which has never been formally appraised by NICE and is commissioned via clinical policy, and oral migalastat, NICE HST4 with a patient access scheme, for the roughly 35-50% of patients whose GLA mutation is amenable, confirmed via an assay available at three NHS genetics labs. On treatment, UK FOS data shows renal function stabilisation in around 70% of patients.
Diagnosis is well-characterised; the amenable-mutation split still decides which therapy a patient gets.
Five questions this report answers:
Q1 - How does the NHS specialist-centre network shape diagnosis and outcomes tracking for UK Fabry disease?
Q2 - What share of the UK Fabry population is amenable-mutation eligible for oral migalastat?
Q3 - How does free NHS cascade testing drive Fabry diagnosis rates in the UK?
Q4 - What proportion of UK Fabry patients show neuropathic pain at some point in their disease?
Q5 - How many NHS centres manage lysosomal storage disorder patients across the UK?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#FabryDisease #NICE #NHS #RareDisease #LysosomalStorageDisorder #UK
Live report page: https://axlrx.ai/fabry-disease/uk/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
GCC Fabry disease access is infrastructure-gated, not formulary-gated: both ERT and oral therapy are covered, yet diagnosis in women lags.
Fabry disease prevalence in GCC males is estimated at 1 in 20,000 to 30,000 versus roughly 1 in 40,000 globally, with specific Arabian Peninsula founder mutations documented at KFSH&RC that create family clusters of 4 to 8 affected males across 2 to 3 GCC generations. Total diagnosed Fabry patients across the GCC number approximately 200 to 300, but true prevalence is likely 3 to 5 times higher given the diagnostic gap, especially in heterozygous females. GCC male patients present with more advanced renal involvement at diagnosis than European cohorts, a median GFR of 45 to 55 mL/min versus 65 to 75 mL/min in Europe.
Heterozygous female Fabry disease, which causes significant morbidity including GFR decline, white matter lesions, and cardiomyopathy despite X-linked inheritance, is systematically under-identified across the GCC: women rarely undergo cascade screening after a male family member's diagnosis. Estimated female Fabry patients run 2 to 3 times the male burden, yet diagnosed female cases represent fewer than half the male diagnosis rate. Both enzyme replacement therapy (agalsidase beta) and oral chaperone therapy (migalastat, for amenable mutations) are NPHC-covered, but migalastat uptake is constrained by HEK cell assay availability limited to KFSH&RC alone.
Women carry most of the undiagnosed Fabry disease burden in the GCC.
Five questions this report answers:
Q1 - How many GCC Fabry patients remain undiagnosed once corrected for the female screening gap?
Q2 - Why do GCC male Fabry patients present with more advanced renal disease than European cohorts?
Q3 - What does the single HEK assay bottleneck mean for migalastat uptake against ERT?
Q4 - What diagnostic and access barriers define the addressable GCC Fabry disease market?
Q5 - Why does GCC Fabry disease access depend on infrastructure rather than formulary coverage?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#FabryDisease #RareDisease #LysosomalStorageDisorder #GCCHealthcare #DiseaseLandscape
Live report page: https://axlrx.ai/fabry-disease/gcc/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
Dravet syndrome hits 1 in 15,700 US births and carries one of epilepsy's highest documented SUDEP rates.
Dravet syndrome is a severe developmental and epileptic encephalopathy that begins in the first year of life, typically with prolonged, often fever-triggered seizures in a previously normally developing infant. A US population-based study at Kaiser Permanente Northern California put incidence at 1 per 15,700 births, roughly twice the earlier estimate of 1 in 40,000, with a likely-pathogenic de novo SCN1A mutation identified in six of eight clinical cases, or about 1 in 20,900. All identified infants had febrile seizures, and most had prolonged seizures lasting more than 10 minutes by age one.
The burden extends well beyond seizure count. In a 100-patient cohort followed for a median of 17 years, 17 patients died at a median age of 7; the syndrome-specific mortality rate was 15.84 per 1,000 person-years and the SUDEP rate 9.32 per 1,000, the highest documented for any epilepsy syndrome and far above the roughly 5.1 per 1,000 reported for refractory epilepsy in adults. Near-universal developmental slowing and intellectual disability compound the burden, making Dravet a lifelong, multi-system condition rather than a seizure disorder alone.
Mortality risk, not just seizure count, defines Dravet's true disease burden.
Five questions this report answers:
Q1 - What is the US incidence of Dravet syndrome, and how has genetic testing changed the estimate?
Q2 - What is the seizure, developmental and mortality burden across Dravet's natural history?
Q3 - How does SCN1A confirmation gate access to Dravet-specific therapy?
Q4 - How common is Dravet syndrome in the United States today?
Q5 - What is the SUDEP and mortality risk for Dravet patients?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#DravetSyndrome #SCN1A #Epilepsy #RareDisease #Pediatrics #USHealthcare
Live report page: https://axlrx.ai/dravet-syndrome/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
Free NHS SCN1A testing confirms 75% of UK Dravet diagnoses, feeding a NICE-sequenced cannabidiol-then-fenfluramine treatment algorithm.
Dravet syndrome is a severe, genetically defined developmental and epileptic encephalopathy, with de novo SCN1A pathogenic variants confirmed in an estimated 80% to 90% of UK cases and clinical molecular confirmation running at roughly 75%. An estimated 400 to 500 patients live with Dravet syndrome in the UK. The NHS Genomic Medicine Service offers SCN1A testing free of charge as part of an epilepsy gene panel to any patient presenting with febrile-seizure-onset epilepsy, with a standard turnaround of 8 to 16 weeks and a fast-track route of under 2 weeks for infantile encephalopathy presentations.
Management runs on a NICE-defined sequence rather than physician discretion: valproate and clobazam first, with sodium-channel blockers contraindicated and documented, then cannabidiol, Epidiolex, NICE TA614 from 2019, added and reassessed at 12 weeks, then fenfluramine, Fintepla, NICE TA887 from 2022, added for inadequate responders. Both agents require prescription through one of 25 NHS Highly Specialised Service paediatric epilepsy centres, and fenfluramine carries a mandatory cardiac monitoring obligation, the Fintepla Cardiac Monitoring Scheme. SUDEP risk of 2% to 18% lifetime is a structural feature of NHS management: NICE guideline NG217 mandates a SUDEP risk discussion at every epilepsy review.
Treatment sequence here follows NICE guidance, not physician discretion.
Five questions this report answers:
Q1 - How does the NHS GMS free SCN1A gene panel shape UK Dravet diagnosis rates?
Q2 - What does the NICE TA614/TA887 cannabidiol-then-fenfluramine sequence mean for positioning a new therapy?
Q3 - How does SUDEP risk factor into UK Dravet commercial and medical-affairs planning?
Q4 - Where is the unmet need in the UK Dravet syndrome treatment pathway?
Q5 - What cardiac monitoring obligation applies to fenfluramine under the Fintepla Cardiac Monitoring Scheme?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#DravetSyndrome #NICE #NHS #Epilepsy #UKHealthcare #DiseaseLandscape
Live report page: https://axlrx.ai/dravet-syndrome/uk/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
